And joining. you Sean. morning, thank Good for
about result six a landmark for we're So we these from away consider patients. months pretty what would
of well care as market quite I backup think as cycle amongst the the their health as as, the substantially. both patients the a through on aware, and frankly, Sean, basis regular well payers these in dissatisfaction patients prescribers well you're given pretty cost systems
be get to the good results of program As goal would presuming looks FDA through to and So get in XXXX. out referenced, what one Angela in year we scope this exactly four Phase had like? the have to September, us in X quarter down quarter cash
So will exactly time out figure we have the what program to Phase X entail.
the the you with of particular in could concordance trial, we of of albeit endpoints, guarantee, really the never endpoint, that the size cetera. of trial unblinding through trial, requirements duration scope been that has the many NDAs the back look a the case, the all approved we're make drugs, Sean, in are this with for Phase if will We size, September the three X, designed et consistent the
of So part this we potentially designed our frankly registration be program package. to
given include from study will is therapy one that this so remaining or forward clinical the a case tell the believe, to components. to assess versus trial stand-alone here placebo. famciclovir And remaining celecoxib, we'll IMS-X statistical multifactorial the will, two versus relative significance trials will goal of a show of of be independent the contribution trial And whether FDA move can't obviously, while potentially or it's combination do alignment. we the the I part And studies, only perspective, two where certainly placebo. as that one multifactorial the you stand-alone trial We required make you subject to if is and characterize, a again IMC-X would
requirement. doesn’t of to fast kind This that forwarding our on thoughts likely us. Just scare
in on studied therapy probably shows and actually the which hope As and put these profound It's see our monotherapy has And results treat our independently is inhibitors you website Xb fibromyalgia NSAIDs trial. that been is Phase well fibromyalgia that are the to the that. as things and opinion and been a two failed saw you together get X antiviral COX-X studied have only aware, when we COX-X, that performed Phase you in well. that in in to published
trial do to determine Phase a the as and to So hoping in and best trial. that data decide we only we for want we're we this to And the X, trial. path one from bring forward want explore but shareholders. raise, FDA's will doing not partner what worried that do feedback and And are can Virios frankly, you ultimately, then capital part of the about
